GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California. Show more

1525 O’Brien Drive, Menlo Park, CA, 94025, United States

Diagnostics & Research
Healthcare
Start AI Chat

Market Cap

1.677B

52 Wk Range

$20.44 - $118.84

Previous Close

$43.03

Open

$42.71

Volume

3,463,050

Day Range

$42.47 - $52.00

Enterprise Value

1.793B

Cash

540.1M

Avg Qtr Burn

-63.25M

Insider Ownership

4.48%

Institutional Own.

75.32%

Qtr Updated

09/30/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date